Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2022

07.01.2022 | Breast Oncology

Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan

verfasst von: Takaaki Konishi, MD, Michimasa Fujiogi, MD, Ayaka Sato, MD, PhD, Nobuaki Michihata, MD, MPH, PhD, Ryosuke Kumazawa, MPharm, Hiroki Matsui, MPH, Kiyohide Fushimi, MD, PhD, Masahiko Tanabe, MD, PhD, Yasuyuki Seto, MD, PhD, Hideo Yasunaga, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although neoadjuvant chemotherapy (NAC) has become common for breast cancer, its impact on short-term surgical outcomes and the feasible chemotherapy–surgery interval remain unclear. Using a Japanese nationwide database, this study investigated the impact of NAC on short-term outcomes following breast cancer surgery.

Methods

In this study of 11,722 patients with NAC and 120,538 patients without NAC who underwent surgery for stage 0–III breast cancer July 2010–March 2017, to cancel out site-specific effects, we generated a 1:4 matched-pair cohort matched for age, institution, and fiscal year of admission. We then conducted multivariable analyses adjusting for potential confounders to compare postoperative complications, duration of anesthesia, and total hospitalization costs. Additionally, we conducted three sensitivity analyses for patients with a short interval from NAC to surgery, patients receiving a particular NAC regimen, and patients undergoing a particular surgical procedure.

Results

In total, the occurrence of postoperative complications was 6.0%, and the median interval from NAC to surgery was 31 (interquartile range, 24–39) days. The two groups did not differ significantly in terms of complications (odds ratio, 0.95; 95% confidence interval, 0.88–1.04), including local and general complications. NAC was significantly associated with shorter duration of anesthesia and lower total hospitalization costs. The sensitivity analyses showed similar results.

Conclusions

Our matched-pair cohort analyses revealed no significant differences in postoperative complications between patients with and without NAC for breast cancer, regardless of the interval, regimen, and surgical procedure. Patients can safely receive surgery and NAC without a lengthened interval.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23:x231–6.CrossRef Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23:x231–6.CrossRef
2.
Zurück zum Zitat Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8-30.CrossRef Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8-30.CrossRef
3.
Zurück zum Zitat Fisher B, Saffer E, Rudock C, Coyle J, Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res. 1989;49:2002–4.PubMed Fisher B, Saffer E, Rudock C, Coyle J, Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res. 1989;49:2002–4.PubMed
4.
Zurück zum Zitat Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991;2:347–54.CrossRef Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991;2:347–54.CrossRef
5.
Zurück zum Zitat Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;15212:96–102.CrossRef Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;15212:96–102.CrossRef
6.
Zurück zum Zitat Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2003;21:4165–74.CrossRef Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2003;21:4165–74.CrossRef
7.
Zurück zum Zitat Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85.CrossRef Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85.CrossRef
8.
Zurück zum Zitat Von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine–capecitabine versus docetaxel–doxorubicin–cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542–51.CrossRef Von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine–capecitabine versus docetaxel–doxorubicin–cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542–51.CrossRef
9.
Zurück zum Zitat Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262:434–8.CrossRef Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262:434–8.CrossRef
10.
Zurück zum Zitat Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220:1063–9.CrossRef Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220:1063–9.CrossRef
11.
Zurück zum Zitat Loibl S, Von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434–42.CrossRef Loibl S, Von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434–42.CrossRef
12.
Zurück zum Zitat Abt NB, Flores JM, Baltodano PA, et al. Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg. 2014;149:1068–76.CrossRef Abt NB, Flores JM, Baltodano PA, et al. Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg. 2014;149:1068–76.CrossRef
13.
Zurück zum Zitat Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW. Surgical outcomes for mastectomy patients receiving neoadjuvant chemotherapy: a propensity-matched analysis. Ann Surg. 2017;265:448–56.CrossRef Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW. Surgical outcomes for mastectomy patients receiving neoadjuvant chemotherapy: a propensity-matched analysis. Ann Surg. 2017;265:448–56.CrossRef
14.
Zurück zum Zitat Decker MR, Greenblatt DY, Havlena J, Wilke LG, Greenberg CC, Neuman HB. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery. 2012;152:382–8.CrossRef Decker MR, Greenblatt DY, Havlena J, Wilke LG, Greenberg CC, Neuman HB. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery. 2012;152:382–8.CrossRef
15.
Zurück zum Zitat Landercasper J, Bennie B, Bray MS, Vang CA, Linebarger JH. Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer? Gland Surg. 2017;6:14–26.CrossRef Landercasper J, Bennie B, Bray MS, Vang CA, Linebarger JH. Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer? Gland Surg. 2017;6:14–26.CrossRef
16.
Zurück zum Zitat Sutton TL, Johnson N, Schlitt A, Gardiner SK, Garreau JR. Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates. Am J Surg. 2020;219:741–5.CrossRef Sutton TL, Johnson N, Schlitt A, Gardiner SK, Garreau JR. Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates. Am J Surg. 2020;219:741–5.CrossRef
17.
Zurück zum Zitat Omarini C, Guaitoli G, Noventa S, et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. Eur J Surg Oncol. 2017;43:613–8.CrossRef Omarini C, Guaitoli G, Noventa S, et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. Eur J Surg Oncol. 2017;43:613–8.CrossRef
18.
Zurück zum Zitat Sanford RA, Lei X, Barcenas CH, et al. Impact of time from completion of neoadjuvant chemotherapy to surgery on survival outcomes in breast cancer patients. Ann Surg Oncol. 2016;23:1515–21.CrossRef Sanford RA, Lei X, Barcenas CH, et al. Impact of time from completion of neoadjuvant chemotherapy to surgery on survival outcomes in breast cancer patients. Ann Surg Oncol. 2016;23:1515–21.CrossRef
19.
Zurück zum Zitat Holmes D, Colfry A, Czerniecki B, et al. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. Ann Surg Oncol. 2015;22:3184–90.CrossRef Holmes D, Colfry A, Czerniecki B, et al. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. Ann Surg Oncol. 2015;22:3184–90.CrossRef
20.
Zurück zum Zitat Kaufmann M, Von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.CrossRef Kaufmann M, Von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.CrossRef
21.
Zurück zum Zitat Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21:555–63.CrossRef Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21:555–63.CrossRef
22.
Zurück zum Zitat Karlsson P, Cole BF, Colleoni M, et al. Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. Int J Radiat Oncol Biol Phys. 2011;80:398–402.CrossRef Karlsson P, Cole BF, Colleoni M, et al. Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. Int J Radiat Oncol Biol Phys. 2011;80:398–402.CrossRef
23.
Zurück zum Zitat Yasunaga H. Real world data in Japan: chapter II the diagnosis procedure combination database. Ann Clin Epidemiol. 2019;1:76–9.CrossRef Yasunaga H. Real world data in Japan: chapter II the diagnosis procedure combination database. Ann Clin Epidemiol. 2019;1:76–9.CrossRef
24.
Zurück zum Zitat Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.CrossRef Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.CrossRef
25.
Zurück zum Zitat Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82.CrossRef Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82.CrossRef
26.
Zurück zum Zitat Inokuchi M, Kutomi G, Kijima Y, et al. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer 2018 edtition. Breast Cancer. 2020;27:4–8.CrossRef Inokuchi M, Kutomi G, Kijima Y, et al. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer 2018 edtition. Breast Cancer. 2020;27:4–8.CrossRef
27.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.CrossRef Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.CrossRef
28.
Zurück zum Zitat Konishi T, Fujiogi M, Michihata N, et al. Comparisons of postoperative outcomes after breast cancer surgery in patients with and without renal replacement therapy: a matched-pair cohort study using a Japanese nationwide inpatient database. Breast Cancer. 2021;28:1112–9.CrossRef Konishi T, Fujiogi M, Michihata N, et al. Comparisons of postoperative outcomes after breast cancer surgery in patients with and without renal replacement therapy: a matched-pair cohort study using a Japanese nationwide inpatient database. Breast Cancer. 2021;28:1112–9.CrossRef
29.
Zurück zum Zitat Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case ratio in matched case-control studies. Am J Epidemiol. 1999;149:195–7.CrossRef Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case ratio in matched case-control studies. Am J Epidemiol. 1999;149:195–7.CrossRef
30.
Zurück zum Zitat Isogai T, Matsui H, Tanaka H, Yokogawa N, Fushimi K, Yasunaga H. Treatments and in-hospital mortality in acute myocardial infarction patients with rheumatoid arthritis: a nationwide retrospective cohort study in Japan. Clin Rheumatol. 2017;36:995–1004.CrossRef Isogai T, Matsui H, Tanaka H, Yokogawa N, Fushimi K, Yasunaga H. Treatments and in-hospital mortality in acute myocardial infarction patients with rheumatoid arthritis: a nationwide retrospective cohort study in Japan. Clin Rheumatol. 2017;36:995–1004.CrossRef
31.
Zurück zum Zitat Konishi T, Fujiogi M, Michihata N, et al. Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan. Breast Cancer Res Treat. 2021;186:731–9.CrossRef Konishi T, Fujiogi M, Michihata N, et al. Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan. Breast Cancer Res Treat. 2021;186:731–9.CrossRef
32.
Zurück zum Zitat Hayashi N, Kumamaru H, Isozumi U, et al. Annual report of the Japanese breast cancer registry for 2017. Breast Cancer. 2020;27:803–9.CrossRef Hayashi N, Kumamaru H, Isozumi U, et al. Annual report of the Japanese breast cancer registry for 2017. Breast Cancer. 2020;27:803–9.CrossRef
33.
Zurück zum Zitat Wiseman JT, Guzman-Pruneda F, Xourafas D, et al. Impact of neoadjuvant chemotherapy on the postoperative outcomes of patients undergoing liver resection for colorectal liver metastases: a population-based propensity-matched analysis. J Am Coll Surg. 2019;229:69-77.e2.CrossRef Wiseman JT, Guzman-Pruneda F, Xourafas D, et al. Impact of neoadjuvant chemotherapy on the postoperative outcomes of patients undergoing liver resection for colorectal liver metastases: a population-based propensity-matched analysis. J Am Coll Surg. 2019;229:69-77.e2.CrossRef
Metadaten
Titel
Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan
verfasst von
Takaaki Konishi, MD
Michimasa Fujiogi, MD
Ayaka Sato, MD, PhD
Nobuaki Michihata, MD, MPH, PhD
Ryosuke Kumazawa, MPharm
Hiroki Matsui, MPH
Kiyohide Fushimi, MD, PhD
Masahiko Tanabe, MD, PhD
Yasuyuki Seto, MD, PhD
Hideo Yasunaga, MD, PhD
Publikationsdatum
07.01.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-11212-6

Weitere Artikel der Ausgabe 5/2022

Annals of Surgical Oncology 5/2022 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.